Biogen's Q4 2024 earnings showed slight revenue growth but Wall Street remains unimpressed due to weak guidance and declining key drug franchises. Leqembi's commercial performance is disappointing ...

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

Biogen has finalised a $900 million payment to settle a whistleblower lawsuit claiming that it paid kickbacks to US doctors to prescribe its multiple sclerosis drugs.

Biogen Pharmachem Industries Ltd share price was down by -0.93% from the previous closing price of ₹1.07. Who are peers of Biogen Pharmachem Industries Ltd? The peers of Biogen Pharmachem ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Mike Elvis Tusubira na Ugandan motorcycle taxi rider wey dey live wit HIV since 2022, wen dem first diagnose am. For am—one of di 1.4 million pipo for Uganda wey dey live wit HIV—USAID na ...

Earnings Report 1.209 USD Q2 2025 Earnings Release 05/07/2025 Earnings Report 1.449 USD Q3 2025 Earnings Release 08/06/2025 Earnings Report 1.091 USD Q4 2025 Earnings Release 11/05/2025 Earnings ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...